MICHAEL MCCARTY

Support funding for the Centers for Disease Control (CDC) Environmental Health Laboratory to "harmonize" clinical diagnostic test results and to establish pediatric reference intervals for in vitro diagnostic (IVD) tests performed on children; support enhanced funding for CDC's Advanced Molecular Detection program; monitor legislation to regulate laboratory-developed IVD tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369); support clinical laboratory and allied health workforce enhancement initiatives, including but not limited to expansion of health workforce programs administered by the Health Resource and Services Administration, funding for the Public Health Workforce Loan Repayment Program and the Bio-Preparedness Workforce Pilot Program; support the Freedom to Invest in Tomorrow's Workforce Act (S. 722/H.R. 1477).

Support funding for the Centers for Disease Control (CDC) Environmental Health Laboratory to "harmonize" clinical diagnostic test results and to establish pediatric reference intervals for in vitro diagnostic (IVD) tests performed on children; support enhanced funding for CDC's Advanced Molecular Detection program; monitor legislation to regulate laboratory-developed IVD tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369); support clinical laboratory and allied health workforce enhancement initiatives, including but not limited to expansion of health workforce programs administered by the Health Resource and Services Administration, funding for the Public Health Workforce Loan Repayment Program and the Bio-Preparedness Workforce Pilot Program; support the Freedom to Invest in Tomorrow's Workforce Act (S. 722/H.R. 1477).

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377); support delay in implementation of Medicare Clinical Laboratory Fee Schedule payment reductions and data reporting requirements under Sec. 216 of the Protecting Access to Medicare Act of 2014.

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377); support delay in implementation of Medicare Clinical Laboratory Fee Schedule payment reductions and data reporting requirements under Sec. 216 of the Protecting Access to Medicare Act of 2014; support Improving Seniors' Timely Access to Care Act of 2024 (H.R. 8702 / S. 4532).

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377); support delay in implementation of Medicare Clinical Laboratory Fee Schedule payment reductions and data reporting requirements under Sec. 216 of the Protecting Access to Medicare Act of 2014; support Improving Seniors' Timely Access to Care Act of 2024 (H.R. 8702 / S. 4532).

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377); support delay in implementation of Medicare Clinical Laboratory Fee Schedule payment reductions and data reporting requirements under Sec. 216 of the Protecting Access to Medicare Act of 2014; support Improving Seniors' Timely Access to Care Act of 2024 (H.R. 8702 / S. 4532).

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377); support delay in implementation of Medicare Clinical Laboratory Fee Schedule payment reductions and data reporting requirements under Sec. 216 of the Protecting Access to Medicare Act of 2014; support Improving Seniors' Timely Access to Care Act of 2024 (H.R. 8702 / S. 4532).

Legislation to regulate laboratory-developed in vitro diagnostic (IVD) tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369); support clinical laboratory and allied health workforce enhancement initiatives, including but not limited to the Medical Laboratory Personnel Shortage Relief Act of 2024 (H.R.9849); support the Freedom to Invest in Tomorrow's Workforce Act (S. 722/H.R. 1477).

Support clinical laboratory and allied health workforce enhancement initiatives, including but not limited to the Medical Laboratory Personnel Shortage Relief Act of 2024 (H.R.9849); support robust funding for the Centers for Disease Control Prevention's Advanced Molecular Detection program.

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377); support delay in implementation of Medicare Clinical Laboratory Fee Schedule payment reductions and data reporting requirements under Sec. 216 of the Protecting Access to Medicare Act of 2014; support Improving Seniors' Timely Access to Care Act of 2024 (H.R. 8702 / S. 4532).

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377); support delay in implementation of Medicare Clinical Laboratory Fee Schedule payment reductions and data reporting requirements under Sec. 216 of the Protecting Access to Medicare Act of 2014.

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377); support delay in implementation of Medicare Clinical Laboratory Fee Schedule payment reductions and data reporting requirements under Sec. 216 of the Protecting Access to Medicare Act of 2014; support Improving Seniors' Timely Access to Care Act of 2024 (H.R. 8702 / S. 4532).

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377); support delay in implementation of Medicare Clinical Laboratory Fee Schedule payment reductions and data reporting requirements under Sec. 216 of the Protecting Access to Medicare Act of 2014; support Improving Seniors' Timely Access to Care Act of 2024 (H.R. 8702 / S. 4532).

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377); support delay in implementation of Medicare Clinical Laboratory Fee Schedule payment reductions and data reporting requirements under Sec. 216 of the Protecting Access to Medicare Act of 2014; support Improving Seniors' Timely Access to Care Act of 2024 (H.R. 8702 / S. 4532).

Legislation to regulate laboratory-developed in vitro diagnostic (IVD) tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369); support clinical laboratory and allied health workforce enhancement initiatives, including but not limited to the Medical Laboratory Personnel Shortage Relief Act of 2024 (H.R.9849); support the Freedom to Invest in Tomorrow's Workforce Act (S. 722/H.R. 1477).

Support funding for the Centers for Disease Control (CDC) Environmental Health Laboratory to "harmonize" clinical diagnostic test results and to establish pediatric reference intervals for in vitro diagnostic (IVD) tests performed on children; support enhanced funding for CDC's Advanced Molecular Detection program; monitor legislation to regulate laboratory-developed IVD tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369); support clinical laboratory and allied health workforce enhancement initiatives, including but not limited to expansion of health workforce programs administered by the Health Resource and Services Administration, funding for the Public Health Workforce Loan Repayment Program and the Bio-Preparedness Workforce Pilot Program; support the Freedom to Invest in Tomorrow's Workforce Act (S. 722/H.R. 1477).

Support funding for the Centers for Disease Control (CDC) Environmental Health Laboratory to "harmonize" clinical diagnostic test results and to establish pediatric reference intervals for in vitro diagnostic (IVD) tests performed on children; support enhanced funding for CDC's Advanced Molecular Detection program; monitor legislation to regulate laboratory-developed IVD tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369); support clinical laboratory and allied health workforce enhancement initiatives, including but not limited to expansion of health workforce programs administered by the Health Resource and Services Administration, funding for the Public Health Workforce Loan Repayment Program and the Bio-Preparedness Workforce Pilot Program; support the Freedom to Invest in Tomorrow's Workforce Act (S. 722/H.R. 1477).

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377) and/or other permanent reforms of Sec. 216 of the Protecting Access to Medicare Act of 2014 (PAMA); support delay in implementation of Medicare Clinical Laboratory Fee Schedule payment reductions and data reporting requirements under Sec. 216 of PAMA.

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377) and/or other permanent reforms of Sec. 216 of the Protecting Access to Medicare Act of 2014 (PAMA); support delay in implementation of Medicare Clinical Laboratory Fee Schedule payment reductions and data reporting requirements under Sec. 216 of PAMA.

Support funding for the Centers for Disease Control (CDC) Environmental Health Laboratory to "harmonize" clinical laboratory test results; support funding for CDC's Environmental Health Laboratory to establish pediatric reference intervals for diagnostic laboratory tests performed on children; support enhanced funding for CDC's Advanced Molecular Detection program; monitor legislation to regulate laboratory-developed in vitro diagnostic tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369); support clinical laboratory and allied health workforce enhancement initiatives, including but not limited to expansion of health workforce programs administered by the Health Resource and Services Administration; funding for the Public Health Workforce Loan Repayment Program and the Bio-Preparedness Workforce Pilot Program; support the Freedom to Invest in Tomorrow's Workforce Act (S. 722/H.R. 1477).

Support funding for the Centers for Disease Control (CDC) Environmental Health Laboratory; monitor legislation to regulate laboratory-developed in vitro diagnostic tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369); support clinical laboratory and allied health workforce enhancement initiatives, including but not limited to expansion of health workforce programs administered by the Health Resource and Services Administration, funding for the Public Health Workforce Loan Repayment Program and the Bio-Preparedness Workforce Pilot Program; support the Freedom to Invest in Tomorrow's Workforce Act (S. 722/H.R. 1477).

Support funding for the Centers for Disease Control (CDC) Environmental Health Laboratory; monitor legislation to regulate laboratory-developed in vitro diagnostic tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369); support clinical laboratory and allied health workforce enhancement initiatives, including but not limited to expansion of health workforce programs administered by the Health Resource and Services Administration, funding for the Public Health Workforce Loan Repayment Program and the Bio-Preparedness Workforce Pilot Program; support the Freedom to Invest in Tomorrow's Workforce Act (S. 722/H.R. 1477).

Support funding for the Centers for Disease Control (CDC) Environmental Health Laboratory to "harmonize" clinical laboratory test results; support funding for CDC's Environmental Health Laboratory to establish pediatric reference intervals for diagnostic laboratory tests performed on children; support enhanced funding for CDC's Advanced Molecular Detection program; monitor legislation to regulate laboratory-developed in vitro diagnostic tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369); support clinical laboratory and allied health workforce enhancement initiatives, including but not limited to expansion of health workforce programs administered by the Health Resource and Services Administration; funding for the Public Health Workforce Loan Repayment Program and the Bio-Preparedness Workforce Pilot Program; support the Freedom to Invest in Tomorrow's Workforce Act (S. 722/H.R. 1477).

Support funding for the Centers for Disease Control (CDC) Environmental Health Laboratory to "harmonize" clinical laboratory test results; support funding for CDC's Environmental Health Laboratory to establish pediatric reference intervals for diagnostic laboratory tests performed on children; support enhanced funding for CDC's Advanced Molecular Detection program; monitor legislation to regulate laboratory-developed in vitro diagnostic tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369).

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377).

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377).

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377); support delay in implementation of Medicare Clinical Laboratory Fee Schedule payment reductions and data reporting requirements under Sec. 216 of the Protecting Access to Medicare Act of 2014.

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377).

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377).

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377).

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377); support delay in implementation of Medicare Clinical Laboratory Fee Schedule payment reductions and data reporting requirements under Sec. 216 of the Protecting Access to Medicare Act of 2014.

Support enactment of the Saving Access to Laboratory Services Act (S. 1000 / H.R. 2377).

Support funding for the Centers for Disease Control (CDC) Environmental Health Laboratory to "harmonize" clinical laboratory test results; support funding for CDC's Environmental Health Laboratory to establish pediatric reference intervals for diagnostic laboratory tests performed on children; support enhanced funding for CDC's Advanced Molecular Detection program; monitor legislation to regulate laboratory-developed in vitro diagnostic tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369); support clinical laboratory and allied health workforce enhancement initiatives, including but not limited to expansion of health workforce programs administered by the Health Resource and Services Administration; funding for the Public Health Workforce Loan Repayment Program and the Bio-Preparedness Workforce Pilot Program; support the Freedom to Invest in Tomorrow's Workforce Act (S. 722/H.R. 1477).

Support funding for the Centers for Disease Control (CDC) Environmental Health Laboratory; monitor legislation to regulate laboratory-developed in vitro diagnostic tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369); support clinical laboratory and allied health workforce enhancement initiatives, including but not limited to expansion of health workforce programs administered by the Health Resource and Services Administration, funding for the Public Health Workforce Loan Repayment Program and the Bio-Preparedness Workforce Pilot Program; support the Freedom to Invest in Tomorrow's Workforce Act (S. 722/H.R. 1477).

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.

Support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for in vitro laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for in vitro laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.

Promote legislative amendments to section 216 of the Protecting Access to Medicare Act of 2014 (PAMA) to improve methodologies for market pricing of the Medicare Clinical Laboratory Fee Schedule; support the Saving Access to Laboratory Services Act (H.R. 8188; S.4449).

Promote legislative amendments to section 216 of the Protecting Access to Medicare Act of 2014 (PAMA) to improve methodologies for market pricing of the Medicare Clinical Laboratory Fee Schedule; support the Saving Access to Laboratory Services Act (H.R. 8188; S.4449).

Promote legislative amendments to section 216 of the Protecting Access to Medicare Act of 2014 (PAMA) to improve methodologies for market pricing of the Medicare Clinical Laboratory Fee Schedule; support the Saving Access to Laboratory Services Act (H.R. 8188; S.4449).

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for in vitro laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.

Support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for in vitro laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for in vitro laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.

Support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for in vitro laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.

Promote legislative amendments to section 216 of the Protecting Access to Medicare Act of 2014 (PAMA) to improve methodologies for market pricing of the Medicare Clinical Laboratory Fee Schedule; support the Saving Access to Laboratory Services Act (H.R. 8188; S.4449).

Promote legislative amendments to section 216 of the Protecting Access to Medicare Act of 2014 (PAMA) to improve methodologies for market pricing of the Medicare Clinical Laboratory Fee Schedule; support the Saving Access to Laboratory Services Act (H.R. 8188; S.4449).

Promote legislative amendments to section 216 of the Protecting Access to Medicare Act of 2014 (PAMA) to improve methodologies for market pricing of the Medicare Clinical Laboratory Fee Schedule; support the Saving Access to Laboratory Services Act (H.R. 8188; S.4449).

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128; support initiatives to improve clinical laboratory testing supply chains.

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128; support initiatives to improve clinical laboratory testing supply chains.

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128; support initiatives to improve clinical laboratory testing supply chains.

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128; support initiatives to improve clinical laboratory testing supply chains.

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128; support initiatives to improve clinical laboratory testing supply chains.

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128; support initiatives to improve clinical laboratory testing supply chains.

Support S. 236, the Tracking COVID-19 Variants Act; support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; monitor legislative efforts to regulated laboratory-developed tests (LDTs); support initiatives to improve COVID-19 testing supply chains.

Appropriations to CDC for harmonization of diagnostic laboratory test results; Appropriations for CDC initiative to establish pediatric reference intervals for clinical diagnostic testing; proposed legislation to establish clinical laboratory workforce development initiatives under the Public Health Service Act and other potential legislative vehicles; prospective legislation to regulate in vitro clinical diagnostic tests, including the Verifying Accurate, Leading-edge IVCT Development (VALID) Act (H.R.6102; S.3404); and the Verified Innovative Testing in American Laboratories (VITAL) Act (S.3512).

Appropriations to CDC for harmonization of diagnostic laboratory test results; Appropriations for CDC initiative to establish pediatric reference intervals for clinical diagnostic testing; proposed legislation to establish clinical laboratory workforce development initiatives under the Public Health Service Act and other potential legislative vehicles; prospective legislation to regulate in vitro clinical diagnostic tests, including the Verifying Accurate, Leading-edge IVCT Development (VALID) Act (H.R.6102; S.3404); and the Verified Innovative Testing in American Laboratories (VITAL) Act (S.3512); Coronavirus relief and stimulus legislation as it relates to clinical laboratories and medical practices; coronavirus testing supply chain issues.

Legislation to regulate in vitro clinical diagnostic tests, including the Verifying Accurate, Leading-edge IVCT Development (VALID) Act (H.R.6102; S.3404); and the Verified Innovative Testing in American Laboratories (VITAL) Act (S.3512); Coronavirus relief and stimulus legislation as it relates to clinical laboratories and medical practices; coronavirus testing and vaccine supply chain issues.

Appropriations for CDC initiative to establish pediatric reference intervals for clinical diagnostic testing; prospective legislation to regulate in vitro clinical diagnostic tests, including the Verifying Accurate, Leading-edge IVCT Development (VALID) Act (H.R.6102; S.3404); and the Verified Innovative Testing in American Laboratories (VITAL) Act (S.3512); Coronavirus relief and stimulus legislation as it relates to clinical laboratories and medical practices; coronavirus testing supply chain issues.

Legislation affecting payments under the Medicare Clinical Laboratory Fee Schedule; coronavirus relief and stimulus legislation as it affects payment for clinical laboratory testing services. Oppose the Strictly Pay for Efficient and Expedited Delivery of Your (SPEEDY) COVID-19 Tests Act (H.R. 8496).

Appropriations for CDC initiative to establish pediatric reference intervals for clinical diagnostic testing; prospective legislation to regulate in vitro clinical diagnostic tests, including the Verifying Accurate, Leading-edge IVCT Development (VALID) Act (H.R.6102; S.3404); and the Verified Innovative Testing in American Laboratories (VITAL) Act (S.3512); Coronavirus relief and stimulus legislation as it relates to clinical laboratories and medical practices; coronavirus testing supply chain issues.

Legislation to regulate in vitro clinical diagnostic tests, including the Verifying Accurate, Leading-edge IVCT Development (VALID) Act (H.R.6102; S.3404); and the Verified Innovative Testing in American Laboratories (VITAL) Act (S.3512); Coronavirus relief and stimulus legislation as it relates to clinical laboratories and medical practices; coronavirus testing and vaccine supply chain issues.

Appropriations to CDC for harmonization of diagnostic laboratory test results; Appropriations for CDC initiative to establish pediatric reference intervals for clinical diagnostic testing; proposed legislation to establish clinical laboratory workforce development initiatives under the Public Health Service Act and other potential legislative vehicles; prospective legislation to regulate in vitro clinical diagnostic tests, including the Verifying Accurate, Leading-edge IVCT Development (VALID) Act (H.R.6102; S.3404); and the Verified Innovative Testing in American Laboratories (VITAL) Act (S.3512).

Appropriations to CDC for harmonization of diagnostic laboratory test results; Appropriations for CDC initiative to establish pediatric reference intervals for clinical diagnostic testing; proposed legislation to establish clinical laboratory workforce development initiatives under the Public Health Service Act and other potential legislative vehicles; prospective legislation to regulate in vitro clinical diagnostic tests, including the Verifying Accurate, Leading-edge IVCT Development (VALID) Act (H.R.6102; S.3404); and the Verified Innovative Testing in American Laboratories (VITAL) Act (S.3512); Coronavirus relief and stimulus legislation as it relates to clinical laboratories and medical practices; coronavirus testing supply chain issues.

Appropriations for CDC initiative to establish pediatric reference intervals for clinical diagnostic testing; prospective legislation to regulate in vitro clinical diagnostic tests, including the Verifying Accurate, Leading-edge IVCT Development (VALID) Act (H.R.6102; S.3404); and the Verified Innovative Testing in American Laboratories (VITAL) Act (S.3512); Coronavirus relief and stimulus legislation as it relates to clinical laboratories and medical practices; coronavirus testing supply chain issues.

Legislation to regulate in vitro clinical diagnostic tests, including the Verifying Accurate, Leading-edge IVCT Development (VALID) Act (H.R.6102; S.3404); and the Verified Innovative Testing in American Laboratories (VITAL) Act (S.3512); Coronavirus relief and stimulus legislation as it relates to clinical laboratories and medical practices; coronavirus testing and vaccine supply chain issues.

Appropriations to CDC for harmonization of diagnostic laboratory test results; Appropriations for CDC initiative to establish pediatric reference intervals for clinical diagnostic testing; proposed legislation to establish clinical laboratory workforce development initiatives under the Public Health Service Act and other potential legislative vehicles; prospective legislation to regulate in vitro clinical diagnostic tests, including the Verifying Accurate, Leading-edge IVCT Development (VALID) Act (H.R.6102; S.3404); and the Verified Innovative Testing in American Laboratories (VITAL) Act (S.3512).

Appropriations to CDC for harmonization of diagnostic laboratory test results; Appropriations for CDC initiative to establish pediatric reference intervals for clinical diagnostic testing; proposed legislation to establish clinical laboratory workforce development initiatives under the Public Health Service Act and other potential legislative vehicles; prospective legislation to regulate in vitro clinical diagnostic tests, including the Verifying Accurate, Leading-edge IVCT Development (VALID) Act (H.R.6102; S.3404); and the Verified Innovative Testing in American Laboratories (VITAL) Act (S.3512); Coronavirus relief and stimulus legislation as it relates to clinical laboratories and medical practices; coronavirus testing supply chain issues.

Support proposed amendments to Section 216 of the Protecting Access to Medicare Act of 2014, including H.R. 3584 (Laboratory Access for Beneficiaries Act); legislation affecting payments under the Medicare Clinical Laboratory Fee Schedule.

Support proposed amendments to Section 216 of the Protecting Access to Medicare Act of 2014, including H.R. 3584 & S. 3049 (Laboratory Access for Beneficiaries Act); legislation affecting payments under the Medicare Clinical Laboratory Fee Schedule.

Proposed amendments to Section 216 of the Protecting Access to Medicare Act of 2014, including H.R. 3584; legislation affecting payments under the Medicare Clinical Laboratory Fee Schedule.